Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor- risk AML patients.
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia / Russo, D.; Candoni, A.; Grattoni, R.; Bertone, A.; Zaja, F.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 83:3(1998), pp. 281-288.
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia
Candoni A.;
1998
Abstract
Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor- risk AML patients.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
